Inhalational Anthrax
Also known as: Inhaled anthrax caused by Bacillus anthracis / Pulmonary anthrax / Pneumonia in anthrax / Anthrax pneumonia (disorder) / Pneumonia anthrax / Pneumonia in anthrax (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB09057 | Anthrax immune globulin human | An immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents. |
| DB06419 | Cethromycin | A ketolide antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, and atypical bacteria that may be useful for treating several conditions including community-acquired pneumonia, inhalation anthrax, plague, and tularemia. |
| DB00537 | Ciprofloxacin | A second generation fluoroquinolone used to treat various susceptible bacterial infections. |
| DB00254 | Doxycycline | A tetracycline antibiotic used to treat a wide variety of bacterial infections. |
| DB01137 | Levofloxacin | A fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria of the upper respiratory tract, skin and skin structures, urinary tract, and prostate, as well as for post-exposure treatment of inhaled anthrax and the plague. |
| DB05336 | Obiltoxaximab | A monoclonal antibody used for prophylaxis or treatment of inhalational anthrax. |
| DB08902 | Raxibacumab | A monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB00537 | Ciprofloxacin | 1 | Completed | 1 |
| DB05336 | Obiltoxaximab | 1 | Completed | 4 |
| DB09057 | Anthrax immune globulin human | Not Available | Not Yet Recruiting | 1 |